Immunopathogenesis of Behçet's disease and treatment modalities

Semin Arthritis Rheum. 2022 Feb:52:151956. doi: 10.1016/j.semarthrit.2022.151956. Epub 2022 Jan 10.

Abstract

Introduction: Behçet's disease (BD) is an auto-inflammatory disease, primarily characterized by recurrent painful mucocutaneous ulcerations.

Methods: A literature search was performed to write a narrative review into the pathogenesis and current treatment options of BD.

Results: The pathogenesis of BD remains to be elucidated, but is considered a genetically primed disease in which an external trigger causes immune activation resulting in inflammatory symptoms. GWAS data show an association between multiple genetic polymorphisms (HLA-B51, ERAP1, IL10 and IL23R-IL12RB2) and increased susceptibility to BD. Bacteria as streptococci, an unbalanced microbiome or molecular mimicry trigger the inflammation in BD. Increased production or responsiveness of pro-inflammatory components of the innate immune response (TLR, neutrophils, NK-cells or γδ T-cells) to these triggers may be a crucial step in the pathogenesis of BD. Additionally to an increased autoinflammatory response there is evidence of a dysregulated adaptive immune system, with a disturbed Th1/Th2 balance, expansion of Th17 cells and possibly a decrease in regulatory T cells, resulting in a surplus in pro-inflammatory cytokines. The inflammation causes a typical clinical phenotype including orogenital ulcerations, uveitis and skin lesions. Treatment is aimed at the aberrations found in the innate (neutrophils and γδ-T cells) and adaptive immune system (TNF-α, INF-γ, IL-1), directed at organ involvement and individualized based on patient characteristics.

Conclusion: We presented an extensive review into the pathogenesis and treatment options of BD.

Keywords: Behçet's disease; Biologicals; Genetics; Pathogenesis; Treatment.

Publication types

  • Review

MeSH terms

  • Aminopeptidases / therapeutic use
  • Behcet Syndrome* / drug therapy
  • Behcet Syndrome* / therapy
  • HLA-B51 Antigen
  • Humans
  • Inflammation / complications
  • Minor Histocompatibility Antigens / therapeutic use
  • Tumor Necrosis Factor-alpha / therapeutic use
  • Uveitis* / etiology

Substances

  • HLA-B51 Antigen
  • Minor Histocompatibility Antigens
  • Tumor Necrosis Factor-alpha
  • Aminopeptidases
  • ERAP1 protein, human